AlphAIAlphAI — Financial news for AI agents
SEC EDGARMAY 271 min read$THC

KERREY J ROBERT sold (to issuer) $105K of THC

KERREY J ROBERT sold (to issuer) 607 shares of TENET HEALTHCARE CORP (THC) at $173.78 ($0.11M total) on 2026-05-22.

Original reporting
SEC EDGAR · KERREY J ROBERT
Published May 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 27, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$THC
Neutral
high confidence
Mentioned
$THC
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCNeutralLow
01

Why it matters

Because the disclosure is limited to share count, price, and a sale-to-issuer code (D), it does not provide new operational or financial information.

02

Market read

A disclosed insider sale to the issuer is typically low-signal; traders may only react if it contributes to a broader insider-selling trend.

03

What to watch

Assess whether there’s a pattern of director/officer selling across recent Form 4s; one-off sales are often non-informative.

Relevance 6/10Timing: Filed 2026-05-26 for a 2026-05-22 transaction; any trading impact would be limited to the disclosure window.

Background

The filing is an SEC Form 4 insider transaction for Tenet Healthcare (THC), reporting a director sale to the issuer on 2026-05-22.

Company-level read

Ticker impact

$THCNeutralHigh confidence
Context

Tenet Healthcare director Kerrey J. Robert sold 607 shares to the issuer for about $105.5K at $173.78/share, per SEC Form 4.

Expected impact

Minimal near-term impact; any move is more likely noise unless repeated insider selling accelerates.

Evidence & confidence

Single small director transaction disclosed via Form 4, with no earnings/guidance/transaction details beyond the sale code and price.

Market effects

Sector

No direct sector read-across; insider Form 4s generally don’t reset healthcare/managed-care expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

If insider sales to the issuer are part of a broader buyback program, the transaction may reflect liquidity/plan mechanics rather than negative views.

Key entities

  • issuer
    TENET HEALTHCARE CORP

    Subject of the Form 4 insider transaction; director Kerrey J. Robert sold 607 shares to the issuer.

  • insider
    KERREY J ROBERT

    Director who sold shares to the issuer; holdings after transaction were 22,442 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

THC insider trading history →

Related articles

OCT 5
$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

simplywall.st2 min
SEP 30
$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

theglobeandmail.com2 min
SEP 26
$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

insidermonkey.com3 min
SEP 20
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

simplywall.st3 min
SEP 9
$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.

simplywall.st2 min